- Home
- MAT vs RYTM Comparison
MAT vs RYTM Comparison
Compare MAT & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MAT | RYTM |
|---|---|---|
| Founded | 1945 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 6.4B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | MAT | RYTM |
|---|---|---|
| Price | $20.77 | $104.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | $24.75 | ★ $129.92 |
| AVG Volume (30 Days) | ★ 2.8M | 609.0K |
| Earning Date | 02-10-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | ★ $5,227,568,000.00 | $174,334,000.00 |
| Revenue This Year | $1.92 | $47.78 |
| Revenue Next Year | $3.47 | $56.52 |
| P/E Ratio | $15.37 | ★ N/A |
| Revenue Growth | N/A | ★ 54.92 |
| 52 Week Low | $13.95 | $45.91 |
| 52 Week High | $22.26 | $122.20 |
Technical Indicators
Market Signals| Indicator | MAT | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 49.92 | 48.13 |
| Support Level | $20.46 | $101.21 |
| Resistance Level | $21.35 | $105.95 |
| Average True Range (ATR) | 0.55 | 5.35 |
| MACD | -0.12 | -0.08 |
| Stochastic Oscillator | 31.94 | 42.51 |
Price Performance
Historical ComparisonAbout MAT Mattel Inc.
Mattel manufactures and markets toy products that are sold to its wholesale and direct to retail customers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, hand-held and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Nearly 60% of its net sales were generated from North America in 2024, with the remainder stemming from international markets.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.